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Abstract
Background:  Prostaglandin H2 synthase (PGHS) is the enzyme that catalyses the two-stage
conversion of arachidonic acid to prostaglandin H2 (PGH2) prior to formation of prostanoids that
are important in inflammation. PGHS isozymes (-1 and -2) are the target for nonsteroidal anti-
inflammatory drugs (NSAIDs).
Given the rekindled interest in specific anti-inflammatory PGHS inhibitors with reduced unwanted
side effects, it is of paramount importance that there are reliable and efficient techniques to test
new inhibitors. Here, we describe a novel in vitro electron paramagnetic resonance (EPR)-based
assay for measuring the activity of PGHS-1.
Methods: We validated a novel in vitro PGHS-1 activity assay based on the oxidation of spin-trap
agent, 1-hydroxy-3-carboxy-pyrrolidine (CPH) to 3-carboxy-proxy (CP) under the action of the
peroxidase element of PGHS-1. This quantifiable spin-adduct, CP, yields a characteristic 3-line
electron paramagnetic (EPR) spectrum.
Results: The assay is simple, reproducible and facilitates rapid screening of inhibitors of PGHS-1.
Aspirin (100 μM, 1 mM) caused significant inhibition of spin-adduct formation (72 ± 11 and 100 ±
16% inhibition of control respectively; P < 0.05). Indomethacin (100 μM) also abolished the signal
(114 ± 10% inhibition of control; P < 0.01). SA and the PGHS-2-selective inhibitor, NS398, failed
to significantly inhibit spin-adduct generation (P > 0.05).
Conclusion: We have demonstrated and validated a simple, reproducible, quick and specific assay
for detecting PGHS-1 activity and inhibition. The EPR-based assay described represents a novel
approach to measuring PGHS activity and provides a viable and competitive alternative to existing
assays.
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Background
Prostaglandins are derived from arachidonic acid (AA) in
a pathway dependent on the PGHS (EC 1.14.99.1) family
of enzymes, which are commonly known as cyclooxygen-
ase (COX), referring to the first step of enzymatic activity.
PGHS converts AA to prostaglandin H2 (PGH2), the pre-
cursor of all prostanoids. The enzyme contains two active
sites: a COX site, where AA is converted into the hydroper-
oxy endoperoxide, prostaglandin G2 (PGG2), and a haem
with peroxidase activity that reduces PGG2 to PGH2 (For
review see [1]). The reduction of PGG2 by the peroxidase
element generates the corresponding alcohol. This reac-
tion has previously been demonstrated to concurrently
oxidise aminopyrine molecules to aminopyrine free radi-
cals [2]. Here, a spin-trapping agent, 1-hydroxy-3-car-
boxy-pyrrolidine (CPH) is oxidised to 3-carboxy-proxy
(CP), probably under the action of the peroxidase, in a
similar fashion to that previously seen with aminopyrine
(Fig. 1).
Two structurally similar PGHS isoforms exist (PGHS-1
and PGHS-2) which are encoded by different genes and
the expression of which varies between tissues [3]. PGHS-
1 is often referred to as the 'house-keeping' isoform due to
its regulatory functions in many tissues. PGHS-2 is virtu-
ally undetectable under normal conditions in most tissues
and is often referred to as the 'inducible' isoform due to its
tendency to be expressed in response to inflammatory
stimuli. The exception to this is in the brain and spinal
cord, where PGHS-2 is constitutively expressed and plays
a role in nociception signaling [4].
The importance of PGHS as a therapeutic target has long
been highlighted by the actions of aspirin, [5,6] the first
drug of the family of nonsteroidal anti-inflammatory
drugs (NSAIDs) for use as analgesics, anti-inflammatory
agents and antithrombotic agents. In contrast to other
NSAIDs, such as indomethacin, which reversibly bind at
the COX active site [7], aspirin causes an irreversible inhi-
bition of PGHS by rapidly and selectively acetylating the
hydroxyl group of a serine residue (Ser 530) near the C-
terminus of the enzyme, forming an impediment to the
binding of AA [8-10]. The ensuing irreversible PGHS inhi-
bition requires de novo synthesis of the enzyme for subse-
quent production of prostaglandins.
Interest in PGHS has been re-ignited recently on account
of two advances in the development of novel NSAIDs.
Firstly, nitroaspirins [11-14] are being developed in an
effort to overcome the gastrotoxic side-effects of aspirin
that represent the major limitation to its therapeutic use
[15-17]. Nitroaspirins make use of the protective effects of
nitric oxide (NO) to compensate for the potentially dam-
aging impact of aspirin-mediated depletion of protective
prostaglandins in the gastric mucosa. Secondly, the sug-
gestion that the gastrotoxic side effects of aspirin are due
to the inhibition of housekeeping PGHS-1, whereas its
anti-inflammatory effects are due to inhibition of PGHS-
2, led to the development of selective inhibitors of the
COX-2 activity of PGHS-2, in the hope that the beneficial
effects could be retained without injury to the gastric
mucosa [18]. However, recently, several of these new
selective PGHS-2 inhibitors have been withdrawn due to
mounting evidence of an increased risk of stroke. The
increased risk of thrombus is thought to be due to inhibi-
tion of PGHS-2 in endothelial cells leading to down regu-
lation of anti-thrombotic prostaglandins (such as
prostacyclin) in relation to the unaffected PGHS-1 derived
thromboxanes [19-21].
Given the intense interest in PGHS activity and inhibition,
it is perhaps surprising that relatively few assays for the
activity of this enzyme have been developed. Amongst the
most popular techniques is the measurement of throm-
boxane B2 (TXB2), the stable metabolite of PGH2-derived
TXA2, as a marker of PGHS activity [22]. Alternatively,
measurement of oxygen consumption using an oxygen
electrode [23,24], assays using radio-labelled substrate
[25] and immunoassays for the prostaglandin products
[23] can also be applied. More recently, a commercial
chemiluminescent assay (Axxora, Nottingham, UK) has
Schematic diagram showing the peroxidase activity of PGHS Figure 1
Schematic diagram showing the peroxidase activity of PGHS. 
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been developed for use on purified enzyme. The assay
involves the use of labelled substrate that generates a
luminescent product under the action of the hydroperox-
idase element of PGHS, most likely via the generation of
oxidising free radicals.
Electron paramagnetic resonance (EPR) has been previ-
ously utilized to measure free radicals generated by PGHS
as a measure of its activity [26,27]. However these tech-
niques can involve complex mechanisms to trap the short-
lived radical species. For instance in an in vitro assay using
purified PGHS, liquid nitrogen was utilised to stop the
reaction and was required to stabilise the tyrosyl radical
species generated, in order that it could be recorded by
EPR [26]. Another technique which recorded PGHS activ-
ity in mouse keratinocytes relied on the use of the antioxi-
dant glutathione to stabilize the generated radical before
trapping it with DMPO [27].
Here, we present a novel method for assaying the activity
of PGHS-1 in which EPR is used to detect the stable adduct
CP, formed from oxidation of commonly available spin-
trap, CPH [28], under the action of the peroxidase ele-
ment of PGHS-1. The aim of the studies described was to
validate this technique for assaying PGHS-1 activity in
vitro, to determine its effectiveness at establishing the
inhibitory effects of conventional NSAIDs and to confirm
that a COX-2-selective inhibitor was ineffective in this
assay.
Methods
Unless otherwise stated, all drugs and chemicals were pur-
chased from Sigma, Dorset, UK. The assay was performed
at 37°C in 1 ml of Tyrode's buffer (137 mM NaCl, 2.7 mM
KCl, 1.05 mM MgSO4, 0.4 mM NaH2PO4, 12.5 mM
NaHCO3, 5.6 mM Glucose, 10 mM HEPES and 0.8 mM
CaCl2 in deionised water at pH 7.4. 100 units/ml ovine
seminal PGHS-1 was incubated with 1.5 μM haematin (5
min, 37°C) prior to the assay. Data from the manufactur-
ers of the PGHS-1 reveals that 1 unit of enzyme consumes
1 nanomole of oxygen at 37°C in the presence of 1 μM
haematin and 100 μM AA. Aspirin, salicylic acid,
indomethacin, NS398 (Merck Biosciences, Nottingham,
UK) or vehicle control (DMSO, 1%) was added and left to
incubate for a further 10 min prior to addition of the spin-
trap, CPH (1 mM; Axxora). At this point (t = -2 min), a
baseline EPR measurement was taken (MS200, Magnet-
tech, Germany. Instrument settings: B0-field, 3356 gauss;
sweep width; 50 Gauss, sweep time, 30 sec; modulation
amplitude, 1500 mGauss; microwave power, 20 mW). 2
min later, 100 μM AA (as sodium salt) was added (t = 0).
Further EPR readings were taken at t = 1.5 (the earliest
timepoint at which readings could consistently be taken
after addition of AA), 4 and 6 min. The suicidal nature of
PGHS-1 activation means that the period of activation is
anticipated to be complete within ~1 min of AA addition
[3].
The results are corrected for any auto-oxidation of spin-
trap by subtraction of values recorded from a duplicate
sample run in the absence of AA. The intensity scale on the
y-axis of all graphs is an arbitrary scale based upon the
area under the curve of the first derivative traces generated.
Statistical analyses
All statistical tests were performed using GraphPad Prism
version 4. P < 0.05 was considered to be statistically signif-
icant. Tests performed were either 1-way ANOVA with
Dunnett's post-test or 2-way ANOVA, as indicated in the
text.
Results
Time-dependent adduct generation by PGHS-1
Addition of AA caused a time-dependent increase in the
characteristic 3-line EPR spectrum for a spin-adduct with
the unpaired electron in the vicinity of a nitrogen atom
(Fig 2a). The majority of the reaction was complete by the
time the first reading was taken (t = 1.5 min). The signal
developed rapidly before the first reading (244 intensity
units.min-1), but subsequently slowed to a relatively con-
stant rate (65 intensity units.min-1) over the following 4.5
min of the assay (Fig 2b, n = 9–12); the equivalent exper-
iment without AA failed to show the initial rapid rise and
was significantly lower than the AA-treated sample
throughout (p = 0.02, 2-way ANOVA, repeated measures).
An inter-sample coefficient of variation of 0.18 (18%) was
calculated from the control data obtained. From these
data, it was determined that t = 1.5 min was an appropri-
ate point at which to compare free radical generation
between control and NSAID-treated PGHS-1, given that
spin-adduct generation in response to AA had peaked –
subsequent adduct formation was at an equivalent rate in
control and AA-treated samples and was likely to be due
to non-specific auto-oxidation of CPH.
Inhibitory effect of aspirin and salicylic acid
The impact of pre-incubation of PGHS-1 with different
concentrations of aspirin that spanned the known thera-
peutic range (10 μM – 1 mM) is shown in Fig 3. Our
results indicate that aspirin concentrations of 100 μM and
1 mM caused significant inhibition of spin-adduct forma-
tion at the 1.5 min time-point (to 72 ± 11 and 100 ± 16%
of control respectively; P < 0.05 for both compared to con-
trol, 1-way ANOVA followed by Dunnet's post-hoc analy-
sis).
Parallel experiments with salicylic acid (SA, 10 μM – 1
mM; n = 6) showed that a 10 min pre-incubation with SA
failed to significantly inhibit generation of the spin-
adduct, even at the highest concentration (P > 0.05).Journal of Inflammation 2006, 3:12 http://www.journal-inflammation.com/content/3/1/12
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Comparative pharmacology of PGHS-1 and PGHS-2 
inhibitors
Equivalent concentrations (100 μM) of the recognized
non-selective PGHS inhibitors, aspirin and indomethacin
both significantly (P < 0.05 and P < 0.01 respectively)
inhibited generation of the EPR-detectable spin adduct at
1.5 min (72 ± 11 and 114 ± 10% inhibition of control
response respectively), but the PGHS-2-selective inhibi-
tor, NS398 had no effect (P > 0.05) on this assay of PGHS-
1, despite its use at a concentration which is in excess of
that required to significantly inhibit PGHS-2 [29] (Fig 4).
Discussion
Here we have validated a new, quick, simple and repro-
ducible method for detecting PGHS-1 activity and inhibi-
tion in vitro. The principle of the assay was based on the
concomitant oxidation which occurs with the reduction
of PGG2 by the peroxidase element of PGHS [2]. This oxi-
dation can be exploited in the absence of antioxidant glu-
tathione to oxidise spin-trapping agent CPH to the stable
adduct, CP which generates a characteristic 3-line EPR
spectrum. The amplitude of the EPR signal is proportional
to the amount of adduct generated.
Our results indicated that oxidation of CPH by the iso-
lated PGHS-1 enzyme upon addition of the enzyme sub-
strate, AA, was sufficient to be easily detectable by EPR.
The initial peak in the detected signal recorded at the first
reading, had by the subsequent time-points slowed to a
rate that was equivalent to the signal generation from sub-
strate-free enzyme, most likely due to autoxidation of the
spin trap. The loss of specific enzyme-mediated radical
generation is unsurprising, given the well-recognised sui-
cidal nature of activated PGHS-1 [3]. From these time-
course experiments, we selected a 1.5 min time-point for
subsequent comparative studies because by this time the
Comparative effects of SA and recognized NSAIDs (all 100  μM) on EPR signal intensity measured at t = 1.5 min Figure 4
Comparative effects of SA and recognized NSAIDs (all 100 
μM) on EPR signal intensity measured at t = 1.5 min. *P < 
0.05, **P < 0.01; 1-way ANOVA with Dunnett's post-hoc 
test vs. control: n = 6–10.
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(a) Sample EPR spectra obtained in the absence (control;  PGHS + AA) and presence of aspirin (100 μM or 1 mM) after  correction for background autoxidation Figure 2
(a) Sample EPR spectra obtained in the absence (control; 
PGHS + AA) and presence of aspirin (100 μM or 1 mM) after 
correction for background autoxidation. EPR settings: B0-
field, 3356 gauss; sweep width; 50 Gauss, sweep time, 30 sec; 
modulation amplitude, 1500 mGauss; microwave power, 20 
mW. (b) Mean data for development of EPR signal intensity 
(AU) with time in the absence (control; PGHS + AA) and 
presence of aspirin (100 μM). In both cases, substrate (AA) 
was added at t = 0 min. P = 0.02, 2-way ANOVA, repeated 
measures: n = 9–12.
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Effect of aspirin and salicylic acid (10 μM – 1 mM) on EPR sig- nals generated from PGHS-1 after treatment with substrate  (AA) Figure 3
Effect of aspirin and salicylic acid (10 μM – 1 mM) on EPR sig-
nals generated from PGHS-1 after treatment with substrate 
(AA). In each case, incubations with aspirin or SA were for 
10 min prior to the baseline EPR reading (t = -2 min, not 
shown). AA was added at t = 0 min and readings shown were 
taken at t = 1.5 min. *P < 0.05, **P < 0.01; 1-way ANOVA 
with Dunnett's post-hoc test vs. control: n = 8–10.
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AA-dependent free radical generation was complete but
the signal was not significantly enhanced by autoxidation
of the spin trap.
Aspirin pretreatment (10 min) was shown to have a con-
centration-dependent inhibitory effect in the published
range [30], but the acetyl-free counterpart, SA, failed to
significantly inhibit enzyme activity. The lack of effect of
SA indicates that aspirin-mediated inhibition of the
enzyme is dependent on the acetyl group, the moiety
involved in PGHS inhibition, and not due to a non-spe-
cific antioxidant effect. SA was not expected to have any
effect in this assay because it is known not to affect PGHS-
1 or 2 activity [31] except in intact cells [30], possibly by
suppressing PGHS-2 transcription in response to exoge-
nous stimuli [32]. Furthermore, the reversible, non-spe-
cific PGHS inhibitor, indomethacin [33] was
demonstrated to have a powerful inhibitory effect, whilst
the PGHS-2 specific inhibitor, NS398 at a concentration
known to inhibit PGHS-2 [29] failed to do so. Signal
intensities shown in the figures are after subtraction of an
AA-free control from a parallel experiment to account for
autooxidation of the spin trap. A negative signal (as
observed with indomethacin for example) therefore indi-
cates that the control value was greater than the AA-treated
sample, which might suggest that AA has a slight antioxi-
dant effect on its own.
These results confirm that the assay is relevant for NSAIDs
with different modes of inhibitory action. As purified
PGHS-2 is now available commercially (Sigma), it may be
possible to adapt this assay system to help determine the
specificity of novel PGHS-2 inhibitors.
This assay provides a convenient screening method for
inhibitors of the PGHS enzyme. Whilst various tech-
niques exist to assay the activity of PGHS isoforms, each
has its own disadvantages. For instance, recording the oxy-
gen uptake by PGHS is an option to measure its activity
but this requires high enzyme concentrations and also
accurate control of the initial oxygen concentrations [24].
Optical techniques are prone to interference from col-
oured assay constituents (such as haematin) and require
high AA concentrations. Techniques recording uptake of
radiolabelled substrate [25] can be complex and expen-
sive. Our technique provides quick inexpensive results
that give real-time determination of COX-inhibition. Data
obtained, as demonstrated by percentage inhibition of
control response achieved with aspirin, is comparable to
other in vitro techniques [34-36].
The technique described in the present study also offers a
simpler alternative than previous EPR techniques where
generated radicals are detected following complex radical
stabilization steps [26,27] and thereby providing poten-
tial for less loss of signal. Tsai et al. [26] used dry ice and
liquid nitrogen to stop the reaction and trap the radical.
The recording of spectra was then carried out under liquid
nitrogen. By comparison, our method uses direct oxida-
tion of a spin-trap to generate an adduct that is sufficiently
stable to allow successive time-point readings to be taken
without the need to freeze the sample at the required
time-point. The method by Schreiber et al. [27] did use a
spin-trap, but required the use of glutathione to reduce an
amine radical to the parent amine, liberating a thiyl radi-
cal which was trapped by DMPO. In our method, the spin-
trap is oxidised directly, thus reducing the potential for
loss of signal. Furthermore, there is some evidence of
rapid signal decay in the Schreiber method; the spectra
show a decrease of the DMPO-thiyl signal during the
course of the measurement, whereby the spectral lines no
longer conform to the expected 1:2:2:1 ratio. By compari-
son, the EPR signal generated in the present technique is
much more resilient and does not decay during the time-
course of experiments.
It is important to recognize the potential limitations of
this assay. Its reliance on the oxidation of CPH might pre-
clude its use in cells, given that the cellular environment
is usually very rich in antioxidants such as GSH, and its
presence at intracellular concentrations (~5 mM) could
effectively compete out the spin-trap and nullify the assay.
The susceptibility of polyunsaturated fatty acids such as
AA to peroxidative attack by reactive oxygen species may
impact on the recorded level of radical if radicals are con-
sumed by free AA in the samples [37,38]. Furthermore, it
is important to recognize that the in vitro nature of the
assay does not account for any absorption, metabolic or
availability issues that might relate to applied NSAIDs.
Conclusion
In summary, we have validated a new, simple, EPR-based
assay for detecting PGHS-1 activity and inhibition. We
have demonstrated it to be sensitive to the inhibitory
effects of conventional NSAIDs (aspirin and indometh-
acin) and not to SA or a PGHS-2 specific inhibitor. In
principle, this assay should be equally applicable to meas-
uring PGHS-2 activity in isolated enzyme. As such, this
assay might prove to be a useful research tool in the ongo-
ing search for novel PGHS inhibitors of both isoforms of
the enzyme.
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